Skip to content
MARKETS / NASDAQ / DARE
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Dare Bioscience, Inc. DARE

14 fiscal years on record · USD · FY2025 reported · SEC filings only
$1.0M
▲ 10429.4% YoY
$-13.4M
$-10.3M
▼ 309.6% YoY
In brief

What this company does

We began assembling our diverse portfolio of assets in 2017 through acquisitions, exclusive in-licenses and other collaborations. The first FDA-approved product to emerge from our portfolio is XACIATO® (clindamycin phosphate) vaginal gel 2%, or XACIATO (pronounced zah-she-AH-toe). XACIATO was approved by the FDA in December 2021 as a single-dose prescription medication for the treatment of bacterial vaginosis in females 12 years of age and older. Our product candidates are in various stages of development, from pre-clinical through a pivotal Phase 3 clinical study.

Written from the business description in Daré Bioscience, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 26 March 2026. Every sentence was checked against that document before publication.

Growth
USD 1.0M
Revenue, FY2025 · full 14-year series below
Revenue $M Net income $M
FY2025 · Revenue 1.0 · Net income -13.4
4M8M-20M20122014201620182020202220242025
Compound annual growth
−53.1%
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−1301 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -1315.5% · Net -1300.7%
-100000%-200000%20122014201620182020202220242025
ROE
FY2023 · ROE -994.7%
-500%20122014201620182020202220242025

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -10.3
2M4M-20M20122014201620182020202220242025

Total assetsUSD 32.5M
EquityUSD 2.8M
CashUSD 24.7M
Current ratio1.14×

Equity funds 9% of total assets.

The 14-year record
14 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 20252024202320222021202020192018201720162015201420132012
Revenue $B0.00.00.00.00.0····0.0·0.00.00.0
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0····
EBITDA $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0····
Income tax $B0.00.00.00.00.00.00.00.00.0·····
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted $−1.20−0.48−4.15−0.37−0.63−0.91−0.97−1.573.56−0.81−1.56−1.60−25.05−36.39
Dividend / sh $··············
Payout %··············
ROE %··−994.7−124.1−205.8·−398.0−167.2−182.8·−174.9···
Shares out B0.010.010.010.080.080.040.020.010.010.000.030.020.00·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 54 reconciliationsAUDITED

Reconciled in 14 of 19 fiscal years. 39 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2012

Share this section

Download image